Lazertinib for NSCLC Harboring Activating EGFR Mutations in TKI naïve Patients
NCT05463224
·
clinicaltrials.gov ↗
PHASE2
Phase
ACTIVE_NOT_RECRUITING
Status
150
Enrollment
OTHER
Sponsor class
Conditions
NSCLC
Interventions
DRUG:
Lazertinib group
Sponsor
Se-Hoon Lee